Goldman Sachs Analyst Reinstates Sell Rating on DBV Technologies Amid VP Treatment Risks
On May 28, Goldman Sachs analyst Rajan Sharma reinstated his sell rating on DBV Technologies S.A. (NASDAQ:DBVT) and set the price target at $7.25.
Dbv Technologies S.a. (DBVT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 1,461,425 | $9,966,919 | 0.11% | |
| 2. | Yiheng Capital Jonathan Guo | 656,309 | $4,476,027 | 0.42% | |
| 3. | Boxer Capital Aaron Davis And Christopher Fuglesang | 0 | $0 | 0% | |
| 4. | Point72 Asset Management Steve Cohen | 0 | $0 | 0% | |
| 5. | Vivo Capital Albert Cha And Frank Kung | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.83 | 17,094 | 17,094 | 2024-03-08 | Filing | ||
| $0.89 | 1,825 | 1,825 | 2024-02-06 | Filing | ||
| $1.52 | 12,000 | Director | 12,000 | 2023-08-25 | Filing | |
| $1.62 | 15,000 | Director | 20,000 | 2023-08-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.84 | 397 | 110,113 | 2025-05-22 | Filing | ||
| $0.85 | 600 | 110,510 | 2025-01-30 | Filing | ||
| $0.57 | 565 | 111,110 | 2024-11-25 | Filing | ||
| $0.53 | 342 | 111,675 | 2024-11-22 | Filing | ||
| $0.54 | 2,350 | 112,017 | 2024-11-21 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 163,487 | $1,114,981 | 0% | |
| 2. | 95,460 | $651,037 | 0.01% | |
| 3. | 40,271 | $274,648 | 0% | |
| 4. | 37,095 | $252,988 | 0.21% | |
| 5. | 8,347 | $56,927 | 0% |
News See All
Why These 15 Healthcare Stocks Are Surging in 2025
After lagging behind the broader market in 2024, many healthcare stocks are making a comeback this year.
DBV Technologies S.A. (NASDAQ:DBVT) Q2 2024 Earnings Call Transcript
Operator: Welcome to the DBV Second Quarter Financial Results and Business Update Conference Call. All participants will be in a listen-only mode.
DBV Technologies S.A. (NASDAQ:DBVT) Q4 2023 Earnings Call Transcript
Operator: Apologies for the late start of our conference. Welcome to the DBV Full Year 2023 Financial Results and Business Update Conference Call. All participants will be in listen-only mode.
DBV Technologies S.A. (NASDAQ:DBVT) Q3 2023 Earnings Call Transcript
Operator: Welcome to the DBV's Third Quarter Financial Results and Business and Regulatory Update Conference Call. [Operator Instructions] Please note this event is being recorded.
DBV Technologies S.A. (NASDAQ:DBVT) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to the DBV Technologies Second Quarter Financial Results Conference Call. My name is Vaishnavi, and I am the operator for this call.
DBV Technologies S.A. (NASDAQ:DBVT) Q4 2022 Earnings Call Transcript
Operator: Good day, and welcome to the DBV Technologies Full Year 2022 Financial Results Conference Call. Please note this event is being recorded. I would now like to turn the conference over to Ms.
5 Best Medical Stocks Under $10
In this article, we will be looking at the 5 best medical stocks under $10.
DBV Technologies SA (DBVT) Fell Out Of Favor With Hedge Funds
In this article you are going to find out whether hedge funds think DBV Technologies SA (NASDAQ:DBVT) is a good investment right now.
Here is What Hedge Funds Think About DBV Technologies SA (DBVT)
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC.
Billionaire Hedge Funds
